Further, in a report of cohort C of the CHRYSALIS-2 trial, including patients with NSCLC and atypical EGFR mutations treated with amivantamab–lazertinib (n = 105), the reported risk of VTE was 30% [20]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.